OBJECTIVES:Erectile dysfunction (ED) is a common problem for elderly males. Higher serum lipid levels have important role in the pathogenesis, and in this prospective randomized trial, it is aimed to identify the effect of atorvastatin on erectile functions in comparison with regular tadalafil use. MATERIALS AND METHODS: 120 patients with a minimum 3-months history of moderate-to-severe ED were involved. The patients were randomized to receive atorvastatin 10 mg/day, tadalafil 20 mg 3 times/week or no medication. Baseline serum testosterone, lipid levels IEEF and NPT test were performed and repeated after 3 months of treatment, and the 3 groups were compared. RESULTS:Mean age of the whole population was 56 years (31-70). The 3 groups were well balanced for the baseline characteristics. Mean improvement of IIEF score was significantly higher in tadalafil group compared to atorvastatin (P = 0.01) and control group (P = 0.0001). Also atorvastatin showed significantly better improvement compared to control group (P = 0.001). Positive NPT test results in tadalafil group was significantly higher than atorvastatin group (25/40 (62.5%) vs. 16/41 (39%), P = 0.003) and compared to control group (25/40 (62.5%) vs. 3/39 (7.6%), P = 0.0001). At the same time, the difference between group 1 and group 3 was statistically significant (P = 0.001). CONCLUSION:Tadalafil 20 mg three times/week shows better results than 10 mg atorvastatin daily. Atorvastatin alone seems to improve EF compared to not using any medication, and this significance is more prominent in patients with supranormal serum lipid levels. Further studies with subgroups of different serum lipid levels should be conducted.
RCT Entities:
OBJECTIVES:Erectile dysfunction (ED) is a common problem for elderly males. Higher serum lipid levels have important role in the pathogenesis, and in this prospective randomized trial, it is aimed to identify the effect of atorvastatin on erectile functions in comparison with regular tadalafil use. MATERIALS AND METHODS: 120 patients with a minimum 3-months history of moderate-to-severe ED were involved. The patients were randomized to receive atorvastatin 10 mg/day, tadalafil 20 mg 3 times/week or no medication. Baseline serum testosterone, lipid levels IEEF and NPT test were performed and repeated after 3 months of treatment, and the 3 groups were compared. RESULTS: Mean age of the whole population was 56 years (31-70). The 3 groups were well balanced for the baseline characteristics. Mean improvement of IIEF score was significantly higher in tadalafil group compared to atorvastatin (P = 0.01) and control group (P = 0.0001). Also atorvastatin showed significantly better improvement compared to control group (P = 0.001). Positive NPT test results in tadalafil group was significantly higher than atorvastatin group (25/40 (62.5%) vs. 16/41 (39%), P = 0.003) and compared to control group (25/40 (62.5%) vs. 3/39 (7.6%), P = 0.0001). At the same time, the difference between group 1 and group 3 was statistically significant (P = 0.001). CONCLUSION:Tadalafil 20 mg three times/week shows better results than 10 mg atorvastatin daily. Atorvastatin alone seems to improve EF compared to not using any medication, and this significance is more prominent in patients with supranormal serum lipid levels. Further studies with subgroups of different serum lipid levels should be conducted.
Authors: Steven A Grover; Ilka Lowensteyn; Mohammed Kaouache; Sylvie Marchand; Louis Coupal; Emidio DeCarolis; Joseph Zoccoli; Isabelle Defoy Journal: Arch Intern Med Date: 2006-01-23
Authors: Kosmas I Paraskevas; Sotirios A Koupidis; Dimitri P Mikhailidis; Dimitrios G Oreopoulos Journal: Int Urol Nephrol Date: 2009-12 Impact factor: 2.370
Authors: Biljana Musicki; Tongyun Liu; Gwen A Lagoda; Travis D Strong; Sena F Sezen; Justin M Johnson; Arthur L Burnett Journal: J Sex Med Date: 2010-09 Impact factor: 3.802
Authors: D G Hatzichristou; K Hatzimouratidis; E Ioannides; K Yannakoyorgos; G Dimitriadis; A Kalinderis Journal: J Urol Date: 1998-06 Impact factor: 7.450
Authors: Michael C Ling; Terrence D Ruddy; Robert A deKemp; Heikki Ukkonen; Lloyd Duchesne; Lyall Higginson; Kathryn A P Williams; Ruth McPherson; Rob Beanlands Journal: Am Heart J Date: 2005-06 Impact factor: 4.749
Authors: Francesco Montorsi; Alberto Briganti; Andrea Salonia; Patrizio Rigatti; Alberto Margonato; Andrea Macchi; Stefano Galli; Paolo M Ravagnani; Piero Montorsi Journal: Eur Urol Date: 2003-09 Impact factor: 20.096
Authors: Joshua A Beckman; James K Liao; Shauna Hurley; Leslie A Garrett; Daoshan Chui; Debi Mitra; Mark A Creager Journal: Circ Res Date: 2004-06-03 Impact factor: 17.367
Authors: Richard Davis; Kelly R Reveles; Sayed K Ali; Eric M Mortensen; Christopher R Frei; Ishak Mansi Journal: J Sex Med Date: 2014-11-25 Impact factor: 3.802
Authors: Muhammad Ismail Shawish; Bahador Bagheri; Vijaya M Musini; Stephen P Adams; James M Wright Journal: Cochrane Database Syst Rev Date: 2021-01-22